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Effect of calcium electroporation on 
tumour vasculature
Barbara Staresinic  1,2, Tanja Jesenko1, Urska Kamensek1, Stine Krog Frandsen3, Gregor Sersa1,4, 
Julie Gehl  3,5 & Maja Cemazar1,6
Calcium electroporation (CaEP) is a novel anti-tumour treatment that induces cell death by 
internalization of large quantities of calcium. The anti-tumour effectiveness of CaEP has been 
demonstrated in vitro, in vivo, and in preliminary clinical trials; however, its effects on the vasculature 
have not been previously investigated. Using a dorsal window chamber tumour model, we observed 
that CaEP affected to the same degree normal and tumour blood vessels in vivo, as it disrupted the 
vessels and caused tumour eradication by necrosis. In all cases, the effect was more pronounced in 
small vessels, similar to electrochemotherapy (ECT) with bleomycin. In vitro studies in four different 
cell lines (the B16F1 melanoma, HUVEC endothelial, FADU squamous cell carcinoma, and CHO cell 
lines) confirmed that CaEP causes necrosis associated with acute and severe ATP depletion, a picture 
different from bleomycin with electroporation. Furthermore, CaEP considerably inhibited cell migratory 
capabilities of endothelial cells and their potential to form capillary-like structures. The finding that 
CaEP has anti-vascular effects and inhibits cell migration capabilities may contribute to the explanation 
of the high efficacy observed in preclinical and clinical studies.
Electroporation is a physical method for permeabilization of cell membranes, allowing molecules and ions that 
are normally unable to cross the membrane because of their chemical and physical properties to enter the cell and 
reach their intracellular targets1. ECT combines electroporation and chemotherapeutic drugs to enhance local 
cytotoxicity and limit systemic toxicity2. The most commonly used drugs for ECT are bleomycin and cisplatin3,4.
Recently, a combination of calcium and electroporation has emerged as an anti-tumour treatment. Calcium 
is an important and ubiquitous second messenger involved in the regulation of a wide variety of cellular pro-
cesses, including proliferation and cell death, and its cytosolic concentration is strongly maintained at low levels5. 
Excessive influx and uptake of calcium in cellular storages, such as in the endoplasmic reticulum and mitochon-
dria, signifies cell stress and can lead to overload, which consequently causes cell death through mitochondrial 
dysfunction and subsequent energy production failure6–9. CaEP was initially investigated as a method to turn off 
transfected genes10 and was later investigated for its anti-cancer properties11.
A contributing mechanism of CaEP is ATP depletion, as the cells are exposed to a sudden loss of ATP likely 
due to increased consumption and impaired production of ATP. Other mechanisms may involve activation of 
lipases and proteases and generation of reactive oxygen species (ROS)8,12,13. In the first preclinical study, CaEP 
showed a decrease in viability and amount of ATP in 3 different cancer cell lines in vitro. In the same study, the 
effect of CaEP was tested in vivo on small-cell lung cancer, where complete necrosis was observed in 89% of 
tumours11. Further studies investigated different concentrations of calcium, and dose-dependent decreases in 
viability and intracellular ATP were observed14,15. The effect of CaEP was also tested in spheroids of normal cells 
and cancer cells, all of which responded with a similar extent of ATP depletion; however, the viability of normal 
fibroblast spheroids appeared to be less affected16. Recently, this was confirmed in vivo, where normal skin and 
muscle tissue treated with CaEP were less affected than tumour tissue17. However, normal cells in suspension 
treated with CaEP have shown a similar response to cancer cells, indicating that the toxicity of CaEP is different 
when cells are freely suspended18. The first clinical trial testing CaEP was recently completed and showed similar 
response rates as ECT19. Furthermore, a case report of a patient with a systemic immune response and remission 
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of disseminated malignant melanoma after ECT with bleomycin and CaEP was published, showing that CaEP 
might not only be a local cancer treatment but can also induce a systemic response20.
ECT with bleomycin is already a well-researched and established treatment that has a blood flow modifying 
effect and vascular disrupting action, in addition to direct cytotoxic effects21,22, which may indeed be an impor-
tant contributor to the high clinical efficacy observed. However, electroporation with calcium is a novel approach 
and its effects on the vasculature have not yet been examined. Hence, the aim of our study was to investigate the 
anti-vascular effects of CaEP, in comparison to ECT with bleomycin as a positive control.
Results
CaEP affects cell viability and causes ATP depletion. CaEP exhibited cytotoxic effects in a dose-de-
pendent manner in all cell lines, but with differing sensitivities. IC50 concentrations of calcium and bleomycin 
(combined with electroporation) were calculated from survival curves for each cell line (Fig. 1a–d). Obtained IC50 
values for calcium were 2.2 mM (B16F1, murine melanoma cells), 4 mM (FaDu, human pharynx squamous cell 
carcinoma), 3.1 mM (HUVEC, human umbilical vein endothelial cells) and 5 mM (CHO cells, Chinese hamster 
ovary cells). For bleomycin, IC50 concentrations were 0.87 nM (B16F1), 0.57 nM (FaDu), 0.39 nM (HUVEC) and 
0.069 nM (CHO). The intracellular concentration of ATP after both therapies was also measured (Fig. 1e–h). A 
significant decline in ATP concentration after CaEP was detected in all cell lines, showing a trend similar to that 
observed for cell survival. At the IC50 calcium concentrations, in B16F1 cells, ATP levels dropped to 20–30%, 
in FaDu cells to 70–80%, in CHO cells to 20–30% and in HUVECs to 40–50%. The normal CHO cells were less 
sensitive to CaEP and they appeared to overcome ATP depletion, whereas, after ECT, they exhibited the highest 
sensitivity. B16F1 melanoma cells were the most sensitive to CaEP since there was the most significant drop in 
cell viability and intracellular ATP. ECT with bleomycin also resulted in a dose-dependent decline in cell viability, 
whereas ATP depletion was observed only at the highest doses of bleomycin, where most of the cells were dead. 
Treatment with calcium alone did not show any decrease in survival or ATP concentrations; however, treatment 
with bleomycin alone showed a significant decrease in survival, but not in ATP levels.
CaEP induces cell death. The cell morphology after CaEP or ECT with bleomycin was observed after 
Giemsa staining (Fig. 2a–d). Almost no cell death was observed in control samples, whereas a major increase 
of cell death was observed after CaEP. These findings indicate that necrosis is the most likely cell death mecha-
nism after CaEP, as previously seen in vivo11,17. To confirm observed cytotoxic effects and changed morphology, 
flow cytometric analysis of cells labelled with FITC Annexin V and 7-AAD was performed to determine cell 
death mechanism (Fig. 2e–h). After CaEP cells were predominately necrotic or in late necrotic/apoptotic stage. 
Figure 1. Cytotoxicity and ATP depletion after treatment with CaEP or ECT with bleomycin. (a–d) Relative 
survival of different normal and tumour cell lines 72 hours after treatment with increasing concentrations of 
calcium or bleomycin and in combination with electroporation (AM ± s.e.m.; n = 16 wells in 3 independent 
experiments). (e–h) The relative concentration of intracellular ATP content 1 hour after treatment with 
increasing concentrations of calcium or bleomycin and in combination with electroporation (AM ± s.e.m.; 
n = 4 wells in 3 independent experiments). *p < 0.05, statistical comparisons were performed by one-way 
ANOVA analysis and compared to control groups by Holm-Sidak testing. All data are normalized to the 
untreated or electroporated-only cells.
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Rupture of cell membranes and cell lysis were the most visible features for cells dying by necrosis23. After EP alone 
and ECT with bleomycin, cell swelling was observed. In addition, after ECT some early signs of apoptosis were 
observed24, such as vacuolisation in the cytosol and nuclear condensation; however, this was not confirmed with 
flow cytometric measurements and could represent also other types of cell death (Fig. 2e–h).
CaEP inhibits tube formation and cell migration of endothelial cells. To determine the anti- 
vascular potential, an endothelial cell tube formation assay was performed on HUVECs. The ability of the cells 
to form capillary-like structures (Fig. 3) after CaEP was significantly reduced, as cells were unable to attach to the 
underlying matrix and form the tubes for at least 6 hours after treatment. ECT with bleomycin had no significant 
effect on tube formation. To determine effects of CaEP on other biological properties, such as cell migration, a 
wound healing assay was performed (Fig. 4). Statistically significant inhibition of cell migration after CaEP was 
Figure 2. Cell morphology and type of cell death after CaEP or ECT with bleomycin (BLM). (a–d) Black 
arrows represent necrotic cells with ruptured membranes and cell lysis (example magnified on upper right). 
Green arrows indicate cells with early signs of apoptosis, such as vacuolisation of cytosol (example magnified on 
lower right). Morphological changes were assessed in at least two independent experiments with two parallels. 
(e–h) Percentage of viable cells (negative; green), apoptotic cells (Annexin V positive; purple), late apoptotic/
necrotic cells (Annexin V + 7-AAD positive; blue) and necrotic cells (7-AAD positive; red) after different 
treatments is shown. Each graph corresponds to the cell line in the same row. Bars represent the average of the 
experiment with two parallels repeated twice.
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observed specifically in 20–40% of HUVECs (Fig. 4d), whereas ECT with bleomycin had no such effect in any of 
the tested cell lines.
CaEP has an anti-vascular as well as an anti-tumour effect in vivo. The in vivo anti-vascular effects 
of CaEP were evaluated by intravital microscopy in the dorsal window chamber model in normal and tumour 
blood vessels. Blood vessels were visualized with rhodamine-B labelled dextran on day 3 after treatment to deter-
mine vessel functionality. CaEP disrupted both normal (Fig. 5) and tumour blood vessels (Fig. 6) and caused 
tissue damage, similar to ECT with bleomycin. In all cases, larger vessels were damaged, while their functionality 
was preserved, whereas all smaller vessels in the treated area were destroyed. After 250 mM calcium, blood vessels 
at the injection site were damaged, even without electroporation. Calcium concentrations of 168 mM and 50 mM 
without EP did not affect the functionality of blood vessels. When calcium was combined with electroporation, 
this effect was amplified. The observed effects did not differ between normal and tumour vasculature.
Anti-tumour effects were also observed in B16F1 GFP melanoma tumours (Fig. 6). The effect on tumour 
survival was estimated based on loss of fluorescent signal, and it was followed up to 7 days after therapy in groups 
with combination therapies. Treatment with CaEP of tumours caused almost immediate necrosis, whereas ECT 
with bleomycin caused gradual death of tumour cells. The change in the appearance of a tumour, mainly pre-
sented as extravasation was already seen 1 h after the treatment (data not shown). In the tumours treated with 
CaEP and ECT, fluorescence was detected again on day 7, indicating that tumours started to re-grow.
Histological evaluation was performed 3 days after the treatment. In normal skin (Fig. 7a), calcium alone 
caused minimal extravasation of erythrocytes at 168 mM calcium. This was more pronounced at 250 mM, where 
necrosis of endothelial and muscle cells was also visible. Electroporation alone caused minor swelling (oedema) of 
Figure 3. Reduced ability to form capillary-like structures of HUVEC endothelial cells after CaEP or ECT with 
bleomycin (BLM). (a) Original images of tubular complexes 4 hours after treatment with IC50 concentrations 
of calcium or bleomycin and in combination with electroporation. (b) Analysis of tubular complexes by 
quantification of different properties (number of nodes, junctions, meshes, total branching length and total 
segments length). All data were normalized to non-treated control cells. Comparisons between groups were 
carried out by Holm-Sidak testing following one-way ANOVA, an asterisk indicates the statistically significant 
difference (*p < 0.05). Results represent at least two independent experiments, n = 4 or more wells in each 
experiment. Bars represent AM ± s.e.m.
www.nature.com/scientificreports/
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the tissue. Necrosis of epidermal, endothelial and some muscle cells was observed after CaEP at 50 mM calcium. 
These features were more evident at higher calcium concentrations with scab formation. At 250 mM calcium, a 
typical blue staining of erythrocytes also occurred, showing calcium deposition in tissue. Bleomycin alone did 
Figure 4. Reduced migration potential of HUVEC endothelial cells after CaEP or ECT with bleomycin (BLM). 
(a–c) Original images of wound healing assays taken at different time points after removal of silicone inserts. 
Last shown time point is when experiments were terminated (when controls have sealed). (d) The kinetic 
analysis of cell migration rate (n = 4 wells in at least 2 independent experiments). Bars represent AM ± s.e.m. 
Asterisk indicates statistically significant difference (*p < 0.05) compared to control, performed by Holm-Sidak 
testing following one-way ANOVA. All data are normalized to the untreated cells. Magnified image shows an 
example of the cell-free area (artificially coloured blue), that was quantified at each time point.
www.nature.com/scientificreports/
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not damage the normal tissue, while necrosis of epidermal, endothelial and muscle cells, was observed after ECT 
with bleomycin.
In tumours (Fig. 7b), only the highest concentration of calcium alone (250 mM) resulted in tumour cell 
necrosis, while lower concentrations of calcium and bleomycin alone did not affect the tumour cells. After 
CaEP and ECT with bleomycin, tumour cell necrosis was evident. At day 3 after treatment, progressive necrotic 
changes were observed in the tumours treated with CaEP, which became more evident with increasing calcium 
Figure 5. Damage of normal blood vessels in dorsal window chamber after CaEP or ECT with bleomycin 
(BLM). Bright-field images of vasculature in dorsal window chamber before the therapy (Day 0) and after the 
therapy (Day 1 and 3) and images of fluorescent blood vessels (Rhodamine B fluorescence). For each group, two 
to three mice were randomly assigned.
www.nature.com/scientificreports/
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concentration, resulting in pyknotic cell nuclei and formation of a scab. In tumours treated with ECT with bleo-
mycin, tumour cells were dying from both necrosis and apoptosis.
Discussion
In this study, we demonstrated that CaEP has an anti-vascular effect on both normal and tumour blood vessels. 
CaEP inhibited the formation of capillary-like structures in vitro, and damaged tumour, as well as normal blood 
vessels, in a similar way as that of ECT with bleomycin. Larger vessels, arterioles and venules were less affected, 
and their functionality was preserved.
The anti-tumour effectiveness of CaEP has already been demonstrated in vitro, in vivo and in clinical stud-
ies11,17,19,20,25 but its effect on vasculature has not yet been explored. The doses of calcium used have been 1–5 mM 
CaCl2 for in vitro studies, where sensitivity is very high across different cell lines11,15. For in vivo studies, 168 mM 
has been used11,18,25, and recently, a broader range of concentrations have been explored in vivo17, in which a 
wide range of calcium doses was shown to be effective. In a clinical study on cutaneous tumours19, a dose of 
Figure 6. Damage of tumour blood vessels and tumours in dorsal window chamber after CaEP or ECT with 
bleomycin (BLM). Bright-field images of tumours and blood vessels in dorsal window chamber before the 
therapy (Day 0) and fluorescence images of tumours (green) and blood vessels (red) on day 1 and 3 after the 
therapy. Graphs demonstrate fluorescence area of representative tumours indicating tumour growth normalized 
to day 0 (control – black line; treated tumour – red line). For each group, two to three mice were randomly 
assigned. Due to high melanin content and fast tumour growth, control tumours were monitored for only 3 
days. Only best-responding tumours treated with combined therapy were monitored for up to 7 days (data not 
shown).
www.nature.com/scientificreports/
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220 mM (directly injected into the tumour in a volume equivalent to 50% of the tumour volume) was used in 
order to compensate for loss to the general circulation. In the present study, a range from 50 to 250 mM of cal-
cium chloride has been investigated in vivo; for bleomycin, the standard dose26 has been used. Additionally, to 
further evaluate CaEP, we have chosen 4 different cell lines of varying tissue origin: B16F1 murine melanoma, 
FaDu human pharynx squamous cell carcinoma, CHO cells, and HUVECs. HUVECs were chosen for studying 
vascular effects, B16F1 cells were later on chosen for tumour model in in vivo study. Additionally, the CHO cell 
line was chosen, because it is a common research model in basic electroporation studies. In clinical practice, ECT 
is often used for treatment of head and neck cancers, therefore, to evaluate whether CaEP would be also appli-
cable for this tumour type, we included in the study the FaDu (squamous cell carcinoma) cell line, which is one 
of the most used research models for head and neck tumours. Electroporation with increasing concentrations of 
calcium significantly reduced cell viability in a dose-dependent manner in all cell lines; however, their sensitivity 
to CaEP differed. The least sensitive were normal CHO cells and the most sensitive were B16F1 melanoma cells. 
The observed difference in sensitivity is in line with previous reports on CaEP toxicity11,14. It was demonstrated 
that normal cells have higher expression of calcium pumps, allowing them to remove excess of calcium from the 
cytosol faster than malignant cells17,27, which might be the reason why normal CHO cells were the least sensitive 
to CaEP. However, further studies are needed to explore the underlying mechanisms of different cell sensitivity 
to CaEP. Loss of ATP after CaEP was previously demonstrated where intracellular levels of ATP were measured 
on attached cells with the fluorescent dye quinacrine, and a significant decrease in fluorescence was detected 
at 15 minutes post-treatment15. Similar results have been obtained with different methods in other studies11,18. 
These studies support the hypothesis that cell death induced by CaEP could be a consequence of sudden ATP 
loss and severe impairment of ATP production; however, ATP depletion can also be a result of the certain type 
of cell death, so further studies are needed to explore the causation of observed ATP depletion. In contrast, ECT 
with bleomycin also caused dose-dependent decreases in cell viability, but ATP depletion was evident only at the 
highest doses, where most of the cells were dead. In both viability and ATP graphs, the results were normalized 
to untreated or EP-treated groups; therefore, the effect of EP alone is not shown. EP alone reduced cell survival 
(~25%) and caused some loss of ATP (~10%) in all cell lines. Therefore, the presented results only indicate the 
effect of the calcium and bleomycin that entered the cells.
Figure 7. Tissue damage in DWC after CaEP or ECT with bleomycin (BLM). Samples of two mice per treated 
group were subjected to histological determination of tissue damage. (a) Representative images of normal 
tissue sections that were exposed to the treatment and stained with haematoxylin and eosin. E epidermis, D 
dermis with hair follicles, S subcutaneous tissues with blood vessels, M striated muscle layer. (b) Representative 
images of tumour sections exposed to the treatment. Blue arrow – oedema; black arrow – blood vessels and 
extravasation; green arrow – damaged epidermis; red arrow – muscle necrosis; yellow arrow – tissue necrosis.
www.nature.com/scientificreports/
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According to previous studies, calcium overload can induce both apoptosis and necrosis. Cells commit-
ted to apoptosis but lacking ATP and sufficient clearance by immune cells will ultimately die by (secondary) 
necrosis12,28,29. Excessive uptake of calcium in the mitochondria is known to cause the formation of pores in the 
mitochondrial inner membrane, causing a mitochondrial permeability transition pores that can have destruc-
tive consequences because the mitochondrial inner membrane potential is disrupted. This stops the synthesis 
of ATP, which can compromise cellular homeostasis and lead to cell death by necrosis12. It needs to be pointed 
out, that this is one of the possible scenarios for cell death; in reality, it is probably a mixture of different activated 
pathways since calcium is involved in a broad range of different cellular processes6,30. Additionally, in the stud-
ies on calcium overload induced by nanosecond pulsed electric fields, it was shown that calcium is involved in 
stabilization of pores in the cell membrane. This state was then replaced by sudden pore dilation and/or opening 
of new larger pores and the following cell death was not a consequence of osmotic swelling but rather because 
of membrane rupture. Also, calcium influx induced by nanosecond pulsed electric fields resulted in necrosis as 
a preferential mode of cell death31,32. These findings might be also true for conventional electroporation using 
microsecond pulses. The type of cell death in our study was determined by flow cytometric analysis of the cells 
stained with 7-AAD/FITC Annexin V and morphological changes of the cells. After CaEP, a high increase of 
cells in necrotic or in late necrotic/apoptotic phase i.e. secondary necrosis was seen when compared to control 
groups, which was expected based on the observed ATP depletion and morphological changes. In addition, in 
vivo studies show extensive tumour necrosis in histologically different types of tumour11. In contrast to CaEP, no 
increase in apoptotic and/or necrotic cells after ECT with bleomycin was seen when compared to control groups. 
Bleomycin causes DNA damage by making single- and double-strand breaks, and it induces two types of cell 
death: pseudoapoptosis or mitotic cell death, depending on the number of internalized bleomycin molecules33,34. 
However, in another study using mouse fibrosarcoma (WEHI-164) and normal rat skeletal muscle (L6) cell lines, 
apoptotic cells were also observed at 24 h after CaEP, as determined by Tunel assay35 and recently confirmed by 
ultrastructure analysis27.
One of the hallmarks of the metastatic process is the ability of cells to migrate36. To evaluate whether CaEP has 
an effect on this process, the effect of CaEP on the migration of cells that survived the treatment was investigated. 
Cell migration rates were evaluated with an in vitro wound healing assay. The migration rate of tumour cells was 
not affected after CaEP, similarly was previously shown for ECT with either bleomycin or cisplatin in melanoma 
cells37. However, our data demonstrated inhibition in the migration of HUVECs after CaEP. ECT with bleomy-
cin did not have a statistically significant effect on the migratory potential of any of the cell lines. Furthermore, 
the ability of HUVECs to form capillary-like structures in vitro was tested after CaEP and ECT with bleomy-
cin. The results showed that capillary-like tube formation was inhibited after CaEP, but not after ECT. We also 
observed that cells did not attach to the matrix for several hours after CaEP treatment. The mechanism behind 
this phenomenon could be the depolymerisation of the actin cytoskeleton due to lower intracellular ATP con-
centrations38. It is a well-known fact that the highly dynamic process of cell migration is driven by focal adhesion 
turnover and actin cytoskeleton remodelling. For proper focal adhesion dynamics, the integrity of the mitochon-
dria must be maintained, since its physiology has an important role in cell migration and cytoskeleton dynam-
ics38,39. In addition, actin is also regulated by calcium. Increased levels of calcium lead to fragmentation of F-actin 
fibres, disruption of the actin structure, and detachment of the cell cortex from the cell membrane. Increased 
calcium concentrations destabilize microtubules through calmodulin and activate calpains, which cleave micro-
tubules12,13. Additionally, leakage of ROS as a consequence of mitochondrial impairment can occur40. All these 
factors can disturb actin cytoskeleton polymerisation, leading to the observed inhibition of cell migration and 
tube formation of endothelial cells12. ECT with bleomycin had no significant effect on cell migration and tube 
formation; although it is known that it has an anti-vascular effect in vivo. The reason for this is likely the short 
observation time (up to 6 hours), as bleomycin-induced cell death mainly becomes evident when cells divide33. 
After CaEP, this effect is immediate.
The in vitro results from our study indicated an anti-vascular potential for CaEP; thus, we further investigated 
the effect of CaEP on normal and tumour vasculature in a dorsal window chamber model. Three different calcium 
concentrations in combination with electroporation were compared to ECT with bleomycin, which has a proven 
vascular disrupting action21,22. Lower concentrations of calcium (50 mM and 168 mM) without electroporation 
caused minor blood extravasation; no other damage was observed in normal blood vessels. In contrast, the high 
dose of 250 mM calcium damaged vessels at the injection site. Electroporation potentiates these effects by causing 
severe normal blood vessel and tissue damage (tissue necrosis). ECT with bleomycin affected smaller vessels, 
leaving larger vessels intact and functional, which has been demonstrated in other studies22,41. Similarly, the func-
tionality of some larger vessels was preserved after CaEP as well. The effect of both CaEP and ECT with bleomycin 
on tumour blood vessels was the same as on normal vessels in this model, thus CaEP and ECT with bleomycin 
did not exhibit any selectivity to tumour blood vessels. However, due to the small size of the tumours in the dorsal 
window chamber and the corresponding tumour vasculature consisting of smaller vessels, all tumour blood ves-
sels were destroyed, and only larger, normal blood vessels remained in the treated area (Fig. 8). Similar changes 
in tumours that were viewed in a dorsal window chamber were previously described for ECT with bleomycin in 
a human colon carcinoma tumour model growing in SCID mice22.
When comparing the effect of calcium injection alone versus CaEP on tumour growth, our results indi-
cated that calcium alone had no evident effect on tumour growth of B16F1 melanoma, with the exception of the 
250 mM calcium concentration, which reduced tumour growth. CaEP induced an immediately visible change in 
a tumour; the area of a tumour became darker (extravasation), which was observed while monitoring the animals 
after the therapy (data not shown). A tumour disappeared completely within one day, and the time for regrowth 
of tumours depended on the calcium concentration; the lowest calcium concentration (50 mM) caused only short 
growth delay, while regrowth occurred after 7 days with the higher concentrations. ECT with bleomycin caused 
gradual death of tumour cells, rather than immediate death as for CaEP, and was accompanied by local tissue 
www.nature.com/scientificreports/
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oedema. The tumours completely disappeared after 3 days; however, tumours started to re-grow after 7 days in 
all cases, which might be due to the survival of some tumour cells after CaEP and/or to the preservation of blood 
vessels functionality, thus providing the oxygen and nutrients for the survived tumour cells. In other preclinical 
in vivo studies, the effect of CaEP was determined for tumours growing subcutaneously. Many histologically dif-
ferent types of tumours were tested, and the sensitivity between the tumour types was shown17. According to the 
study, lung carcinoma HT69 was the most responsive, while bladder carcinoma SW780 was the least responsive17. 
As evidenced by the level of necrosis that was observed after 168 mM CaEP in our study, melanoma tumours are 
very sensitive to CaEP. This was also demonstrated in a clinical study19,20. A patient with subcutaneous melanoma 
metastases was first treated with ECT, and then other nodules were treated with CaEP. The treated nodules disap-
peared after both treatments; however, after treatment with CaEP, a strong immune response against melanoma 
cells occurred that also affected non-treated tumours20.
In conclusion, our study is the first to show that CaEP, similar to ECT with bleomycin, has an anti-vascular 
effect on both normal and tumour blood vessels. CaEP inhibited the formation of capillary-like structures in vitro 
and damaged normal and tumour blood vessels in the B16F1 melanoma tumour model in vivo. These results 
show that CaEP has a significant tumour necrosis effect. Our study provides further evidence for the use of CaEP 
in clinical settings.
Methods
Cell lines. B16F1 murine melanoma cells (ATCC) were cultured in Advanced MEM (Thermo Fisher 
Scientific), CHO cells (ATCC) were cultured in Advanced DMEM/F-12 (Thermo Fisher Scientific), HUVECs 
(ATCC) were cultured in Advanced DMEM (Thermo Fisher Scientific), FaDu human pharynx squamous cell 
carcinoma (ATCC) were cultured in Advanced RPMI 1640 (Thermo Fisher Scientific). All culture media were 
supplemented with 5% foetal bovine serum (FBS), 10 mM L-glutamine (Thermo Fisher Scientific), 50 mg/ml 
gentamicin and 100 U/ml penicillin and held in a 5% CO2 humidified incubator at 37 °C.
B16F1 cell line expressing the green fluorescent protein (B16F1 GFP) was prepared by stable transfection with 
pEGFP-N1 plasmid (Invivogen) using electroporation as previously described42 and cultivated with the addition 
of 2 mg/ml of selection antibiotic geneticin (Thermo Fisher Scientific).
Animals. Eight to twelve-week-old female C57BL/6JOlaHsd mice weighing 18–21 g were used in experi-
ments. Mice were kept in quarantine for 2 weeks before the experiment. Specific-pathogen-free housing condi-
tions were provided throughout the period of quarantine and experiment. The experimental procedures were 
Figure 8. Scheme of cytotoxic and vascular effects after CaEP. The left side of the figure represents intact 
normal and tumour vessels and viable tumour cells. On the right side positions of electrodes (marked with black 
lines and shaded area) and effects after CaEP in the treated area are shown, such as dead or dying tumour cells, 
damage to the small blood vessels, which results in extravasation of erythrocytes, damaged but functional larger 
vessels and intact vessels outside of the treated area.
www.nature.com/scientificreports/
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performed in compliance with the guidelines for animal experiments of the EU directive (2010/63/EU) and the 
permission from the Veterinary Administration of the Ministry of Agriculture, Forestry and Food of the Republic 
of Slovenia (permission no. U34401–1/2015/16). In the experiments, 2 mice were randomly assigned to an exper-
imental group with single treatments (control, EP, BLM, Ca) and 3 mice in the combination groups (BLM + EP 
and CaEP).
Drugs and solutions. For in vitro experiments, bleomycin (Bleomycin medac, Medac) was diluted in dis-
tilled water to concentrations of 1.4 × 10−6 M, 1.4 × 10−7 M, 1.4 × 10−8 M, 1.4 × 10−9 M or 1.4 × 10−10 M in a final 
cell suspension. Calcium solution was prepared from CaCl2 × 6H2O in distilled water to 250 mM in the stock 
solution. It was diluted to 5 × 10−3 M, 4 × 10−3 M, 3 × 10−3 M, 2 × 10−3 M or 1 × 10−3 M in a final cell suspension. 
The electrical conductivity (measured with SevenCompact S230 conductometer (Mettler Toledo, Switzerland) 
at 24 °C) and the osmolality (measured by freezing point depression with Knauer cryoscopic unit (model 
7312400000, Knauer, Germany)) of final solutions changed from 0.2 S/m to 0.3 S/m and from 0.16 Osm/kg to 
0.19 Osm/kg, respectively. These changes had no influence on the outcome of electroporation43,44.
For in vivo experiments, 250 × 10−3 M, 168 × 10−3 M and 50 × 10−3 M calcium solutions and 1.4 × 10−3 M ble-
omycin solution diluted in distilled water were used.
Electroporation protocol. Cells were collected by trypsinization and centrifugation, washed in ice-cold 
electroporation buffer (125 mM sucrose, 10 mM K2HPO4, 2.5 mM KH2PO4, 2 mM MgCl2 × 6 H2O) and prepared 
for electroporation as previously described45. Briefly, 50 μl of the suspension (1 × 106 cells) served as a control for 
treatment, while an additional 50 μl was pipetted between two stainless-steel parallel-plate custom-made elec-
trodes (2 mM apart), and 8 square-wave electric pulses (1300 V/cm, 100 μs, 1 Hz) were generated with an electric 
pulse generator GT-01 (Faculty of Electrical Engineering, University of Ljubljana, Ljubljana, SI). Pulses were 
monitored on an oscilloscope Tektronix TDS3012 (Tektronix). After application of electric pulses, cells were 
transferred to a 24-well ultra-low attachment plate and incubated for 5 min at room temperature, then 1 ml of 
culture medium was added to the cells, and the cells were utilized in the different assays (see below).
Cytotoxicity assay. To determine cell viability after treatment with calcium and bleomycin alone or in 
combination with EP, a Presto Blue (Thermo Fisher Scientific P#A13262) assay was performed as previously 
described46. Briefly, from the 1 ml cell suspension (see above), cells were diluted to 1 × 103/100 µl (control groups) 
or 2 × 103/100 µl (EP groups) and transferred to 16 wells per group in a 96-well Tissue culture plate (VWR), each 
well thus containing 1 × 103 cells, when they were exposed to drug alone or 2 × 103 cells exposed to combined 
treatment with EP. The plates were then incubated for 3 days. Relative survival rate values were normalized to EP 
group alone or untreated control group. IC50 concentrations (50% inhibition of survival) were obtained from the 
survival curves of cells exposed to combined treatments.
ATP assay. To determine ATP loss after treatment, ATP levels in the cell lysates were measured. After treat-
ment, 1 × 106 cells were incubated in 1 ml of complete culture media for 1 h at 37 °C in a 5% CO2 atmosphere. 
Afterwards, cells were lysed with boiling distilled water as previously described47. ATP content was determined 
using an ATP determination kit (Molecular Probes P#A22066) according to manufacturer’s instructions, and 
bioluminescence was measured in white 96-well plates. Relative ATP content values were normalized to EP group 
alone or untreated control group.
Giemsa staining. For morphological determination of cell death, cytospins were prepared. Cells (5 × 103), 
treated with IC50 concentrations of the drug alone or in combination with EP, were added to a slide chamber and 
centrifuged for 4 minutes at 1,000 rpm in a cytocentrifuge. The slides were air dried, fixed in absolute methanol 
(approximately 1 h after treatment) and stained with Giemsa’s Azure methylene blue solution (Merck). Images of 
the cells were captured with a DP72 CCD camera connected to Olympus BX-51 microscope.
Determination of cell death mechanisms. Cell death mechanisms were determined with a FITC 
Annexin V Apoptosis Detection Kit with 7/AAD (Biolegend P#640922) according to manufacturer’s instructions. 
Briefly, after 5 minutes post-treatment incubation time, cells were transferred to the 15 ml tubes and washed twice 
by centrifugation. Then, cells were resuspended in Annexin V Binding Buffer and transferred to flow cytometry 
tubes. FITC Annexin V and 7/AAD were added to the cells 40–45 minutes after electroporation and incubated for 
another 15 minutes prior measurement. The measurements were performed using FACSCanto II flow cytometer 
(BD Biosciences). A 488-nm laser was used for the excitation; both 530 and 650-nm band-pass filters were used 
for detection of green and red fluorescence. For each sample, at least 100000 events were measured. The data were 
analysed using BD FACSDiva software version 8.0.1 (BD Biosciences). All debris was excluded for further analysis 
using FSC/SSC scatter plot.
Tube formation assay. To determine the effect of CaEP and ECT on the ability of endothelial cells to form 
capillary-like structures, a tube formation assay was performed on HUVECs. No treatment control, EP control, 
and cells treated with IC50 concentrations (with or without EP) were plated in a density of 2.4 × 104 cells per 
well on a µ-Slide Angiogenesis (Ibidi) covered with a Matrigel® Basement Membrane Matrix Phenol Red-Free 
(Corning) and incubated for 4 hours until the formation of tubular complexes. The cells were then stained with 
Calcein-AM (Merck) and their images were captured with a DP72 CCD camera connected to Olympus IX-70 
inverted fluorescence microscope. Cellular networks were analysed using Angiogenesis Analyzer for ImageJ48 by 
quantifying a number of nodes, junctions and meshes, total branching length and total segments length.
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Wound healing assay in vitro. To determine the migratory capacity of the treated cells, wound healing 
assays were performed49 after treatment with IC50 concentrations alone with or without EP. After treatment, 
4 × 104 cells were plated on a 24-well plate with a silicone insert (Ibidi) that formed a 500-μm ± 50 μm cell-free 
gap after removal. Cells were incubated overnight at 5% CO2 and 37 °C until a confluent cell monolayer was 
formed, then the silicone inserts were removed. Images of the wounds were captured with DP72 CCD camera 
connected to Olympus IX-70 inverted microscope at 0 h (when culture inserts were removed) and then every 
2–4 hours (depending on the cell line used and optimized in preliminary tests), until the wounds of the control 
group were completely sealed (for HUVEC 12 h, CHO 24 h, FaDu 26 h). At each time point, the cell-free area was 
quantified using FIJI image analysis software50 and a kinetic analysis was made from the obtained values. The cell 
migration rate of each experimental group was normalized to the migration rate of untreated cells. The assay was 
not performed in B16F1 cells because these cells have very limited migratory potential.
Dorsal window chamber. For implantation of dorsal window chambers, mice were anaesthetized with an 
anaesthetic solution (ketamine, 125 mg/kg; xylazine 12.5 mg/kg; acepromazine 2.5 mg/kg) injected intraperito-
neally with volumes adjusted to the weight of the animal. The back of the mouse was shaved and depilated with 
a depilatory cream. Mice were kept warm using heating pads throughout the procedure. The dorsal window 
chamber was implanted surgically onto the extended double layer of skin as previously described51. After surgery 
and on the following two days, 50 µl of analgesia (ketoprofen, 3.5 mg/kg) was injected intramuscularly. In the 
experiments investigating the effect of CaEP on tumour vasculature, 2 days after surgery tumours were induced 
by injection of 3.5 × 105 B16F1 GFP cells in 5 µl of physiological solution into the dermis of intact skin in the 
dorsal window chamber with a 29-G needle.
In vivo electroporation and intravital imaging. For intravital imaging, a Carl Zeiss SteREO Lumar 
V12 fluorescence stereomicroscope equipped with a Neo-Lumar S 0.8x objective and an AxioCam MRc5 digital 
camera was used, and effects on tumour and normal vasculature were observed. Mice were anaesthetized with 
isoflurane inhalation anaesthesia and the dorsal window chamber was fixed on a custom-designed holder. Five 
days after implantation (when tumours reached the size of 4–5 mm3), dorsal window chambers were imaged 
followed by treatment (Day 0). Either 5 µl of MiliQ water or different concentrations of calcium or bleomycin (see 
above) were injected intratumourally or intradermally in the dorsal window chamber region. Electrodes were 
placed around the injection site, and good contact between the skin and the electrodes was ensured by using con-
ductive gel. EP was performed immediately after injection by application of 8 (4 + 4) square-wave electric pulses 
given in perpendicular directions through parallel electrodes with an inner distance of 4 mm. Pulsing conditions 
were 1300 V/cm, 100 µs and 1 Hz. Pulses were generated by ELECTRO cell B10 HVLV (LEROY biotech, Betatech, 
Saint-Orens-de-Gameville, France). Dorsal window chambers were imaged once per day for 3 days. On day 3, 
the functionality of normal and tumour blood vessels was visualized with the injection of Rhodamine B-labelled 
dextran (70 kDa; Merck) into the orbital plexus and images of fluorescent blood vessels were taken. Tumours 
treated with a combination of electroporation and calcium or bleomycin were additionally imaged on day 7. The 
fluorescence area was measured for each tumour using FIJI software50.
Histological determination of skin damage. For the histological determination of the skin damage after 
therapy, paraffin-embedded sections were prepared. Mice were sacrificed by cervical dislocation at day 3, and the 
region of skin in the dorsal window chamber was excised. The excised skin was then fixed in zinc fixative for 1 day 
and then stored in 70% ethanol until it was embedded in paraffin for histological observation of skin damage. In 
the direction perpendicular to the skin layers, 5-µm thick sections were cut and stained with haematoxylin and 
eosin. Images were taken with Olympus BX-51 microscope equipped with a digital camera DP72.
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